{"article_title": "Merck to buy Cubist Pharmaceuticals for $8.4 billion", "article_keywords": ["billion", "buy", "cubist", "drugs", "hospital", "sales", "used", "pharmaceuticals", "merck", "drug", "diabetes", "84", "treat"], "article_url": "http://www.marketwatch.com/story/merck-to-buy-cubist-pharmaceuticals-for-84-billion-2014-12-08", "article_text": "Drug giant Merck & Co. agreed to buy antibiotics maker Cubist Pharmaceuticals Inc. for $8.4 billion.\n\nThe deal, which also includes the assumption of $1.1 billion in debt, is worth $102 a share, a 37% premium to Friday\u2019s close.\n\nCubist US:CBST specializes in drugs to treat infectious diseases and other conditions, primarily in a hospital setting. Its flagship drug is Cubicin, an intravenous antibiotic used to treat serious infections that had $967 million in sales in 2013. Analysts expect sales of the drug will continue to rise in coming years.\n\nMerck\u2019s MRK, -0.32% interest in Cubist appears to stem from a strategy announced in 2013 to narrow its focus to areas including diabetes, acute hospital care, vaccines and oncology.\n\nMerck has an aging drug portfolio and its top selling product, diabetes treatment Januvia, isn\u2019t growing like it used to. The company recently got a cancer immunotherapy called Keytruda approved. In August, Merck acquired Idenix Pharmaceuticals Inc., a developer of hepatitis C drugs, for about $3.9 billion.\n\nAn expanded version of this report appears at WSJ.com.\n\nMore from MarketWatch", "article_metadata": {"lifp_basePath": "https://id.marketwatch.com/access", "twitter": {"domain": "marketwatch.com", "description": "Merck says it agreed to buy Cubist Pharmaceuticals for $8.4 billion, and the assumptions of $1.1 billion in debt, as it continues with the strategy to narrow its focus on diabetes, acute hospital care, vaccines and oncology.", "image": {"width": 1320, "identifier": "http://s.marketwatch.com/public/resources/MWimages/MW-CO509_MRK_07_ZG_20140728163618.jpg", "height": 742}, "card": "summary_large_image", "site": {"id": 624413}}, "parsely-author": "Dana Cimilluca", "article.content_group": "marketwatch", "article.section": "Industries", "parsely-type": "post", "description": "Merck says it agreed to buy Cubist Pharmaceuticals for $8.4 billion, and the assumptions of $1.1 billion in debt, as it continues with the strategy to narrow its focus on diabetes, acute hospital care, vaccines and oncology.", "parsely-link": "http://www.marketwatch.com/story/merck-to-buy-cubist-pharmaceuticals-for-84-billion-2014-12-08", "author": "Peter Loftus, Dana Cimilluca", "parsely-title": "Merck to buy Cubist Pharmaceuticals for $8.4 billion", "apple-itunes-app": "app-id=336693422", "parsely-pub-date": "2014-12-08T07:26:00-05:00", "page.site": "marketwatch", "robots": "noarchive,noodp", "fb": {"app_id": 283204329838}, "parsely-section": "MW_Industries", "article": {"publisher": "https://www.facebook.com/marketwatch"}, "viewport": "width=device-width, initial-scale=1, maximum-scale=1", "og": {"site_name": "MarketWatch", "description": "Merck says it agreed to buy Cubist Pharmaceuticals for $8.4 billion, and the assumptions of $1.1 billion in debt, as it continues with the strategy to narrow its focus on diabetes, acute hospital care, vaccines and oncology.", "title": "Merck to buy Cubist Pharmaceuticals for $8.4 billion", "url": "http://www.marketwatch.com/story/merck-to-buy-cubist-pharmaceuticals-for-84-billion-2014-12-08", "image": "http://s.marketwatch.com/public/resources/MWimages/MW-CO509_MRK_07_ZG_20140728163618.jpg", "type": "article"}, "ob": {"image": "http://s.marketwatch.com/public/resources/MWimages/MW-CO509_MRK_07_ZG_20140728163618.jpg"}, "article.id": "1FFD5AC2-7ED4-11E4-B958-9914BC4CC507", "position": 1}, "article_summary": "Drug giant Merck & Co. agreed to buy antibiotics maker Cubist Pharmaceuticals Inc. for $8.4 billion.\nIn August, Merck acquired Idenix Pharmaceuticals Inc., a developer of hepatitis C drugs, for about $3.9 billion.\nCubist US:CBST specializes in drugs to treat infectious diseases and other conditions, primarily in a hospital setting.\nMerck has an aging drug portfolio and its top selling product, diabetes treatment Januvia, isn\u2019t growing like it used to.\nThe deal, which also includes the assumption of $1.1 billion in debt, is worth $102 a share, a 37% premium to Friday\u2019s close."}